KalVista Pharmaceuticals (NASDAQ:KALV) Sets New 12-Month High – Still a Buy?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)’s stock price reached a new 52-week high on Monday . The stock traded as high as $17.30 and last traded at $16.9450, with a volume of 357442 shares traded. The stock had previously closed at $16.91.

Analyst Upgrades and Downgrades

KALV has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, October 8th. Wall Street Zen upgraded KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. JMP Securities increased their price objective on KalVista Pharmaceuticals from $27.00 to $28.00 and gave the company a “market outperform” rating in a report on Friday, September 12th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, November 11th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, KalVista Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $26.63.

KalVista Pharmaceuticals Stock Down 7.3%

The business’s fifty day simple moving average is $12.98 and its two-hundred day simple moving average is $13.27. The company has a market cap of $745.11 million, a PE ratio of -3.74 and a beta of -0.14. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.04. The business had revenue of $13.69 million for the quarter, compared to analyst estimates of $6.03 million. On average, analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Insider Transactions at KalVista Pharmaceuticals

In other news, insider Paul K. Audhya sold 5,296 shares of the stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $13.45, for a total transaction of $71,231.20. Following the transaction, the insider owned 131,831 shares in the company, valued at $1,773,126.95. This trade represents a 3.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Brian Piekos sold 4,471 shares of the business’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $13.45, for a total transaction of $60,134.95. Following the completion of the sale, the chief financial officer directly owned 10,529 shares of the company’s stock, valued at approximately $141,615.05. The trade was a 29.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 31,329 shares of company stock valued at $437,371 in the last three months. 4.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of KALV. Tudor Investment Corp ET AL acquired a new stake in KalVista Pharmaceuticals in the 3rd quarter worth about $24,360,000. Sherbrooke Park Advisers LLC acquired a new position in KalVista Pharmaceuticals in the 3rd quarter valued at $191,000. Qube Research & Technologies Ltd lifted its holdings in KalVista Pharmaceuticals by 234.6% in the 3rd quarter. Qube Research & Technologies Ltd now owns 325,435 shares of the specialty pharmaceutical company’s stock valued at $3,964,000 after purchasing an additional 228,187 shares in the last quarter. Parkman Healthcare Partners LLC boosted its stake in KalVista Pharmaceuticals by 155.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock worth $21,132,000 after purchasing an additional 1,055,940 shares during the last quarter. Finally, Brevan Howard Capital Management LP boosted its stake in KalVista Pharmaceuticals by 319.1% during the 3rd quarter. Brevan Howard Capital Management LP now owns 55,878 shares of the specialty pharmaceutical company’s stock worth $681,000 after purchasing an additional 42,545 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).